EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

SARS-CoV-2 Main Protease Inhibitors Containing 5-Substituted Benzothiazole-2-carbonyl Moieties at the P1′ Site and Their Derivatives

Kohei Tsuji iD, Takuya Kobayakawa, Nobuyo Higashi-Kuwata iD, Takahiro Ishii iD, Kouki Shinohara, Ryusei Yamamoto, Yutaro Miura, Naoya Wada, Hiroaki Mitsuya, Hirokazu Tamamura iD

ACS Omega · 16.09.2025 · 10 (36) · 41608-41619

DOI: 10.1021/acsomega.5c05168 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Omega, online erschienen am 27.08.2025. Verfasst von Kohei Tsuji und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, Laboratory for Biomaterials and Bioengineering, Institute of Integrated Research, Institute of Science Tokyo, Chiy…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: University Fellowship Creation Project for Creating Scientific and Technological Innovation, Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Development of anti-SARS-CoV-2 agents is still required because of the appearance of drug-resistant strains, and targeting the main protease (Mpro) of SARS-CoV-2 is a powerful way to develop therapeutics against COVID-19. To date, we have developed several Mpro inhibitors including compounds 3, 4, TKB245 (6), and TKB248 (7), which have a 4-fluorobezothiazole ketone moiety as a warhead structure. Further studies led to the development of a more potent Mpro inhibitor, TKB272 (8), which has a 5-fluorobenzothiazole ketone moiety. The slight difference in the introduction position of a fluorine atom enhanced its antiviral activity approximately 3-fold for VeroE6 cells and 15-fold for HeLahACE2‑TMPRSS2 cells when TKB272 (8) was compared to TKB245 (6). Herein, we report the synthesis and structure-activity relationship (SAR) studies of TKB272 (8). TKB272 (8) is a promising drug candidate for COVID-19 therapy, and the present data of the SAR studies are useful for the further development of Mpro inhibitors.

Autor:innen und Institutionen

  • Department of Medicinal Chemistry, Laboratory for Biomaterials and Bioengineering, Institute of Integrated Research, Institute of Science Tokyo, Chiyoda-ku 101-0062, Tokyo, Japan.
  • Department of Refractory Viral Infections, National Institute of Global Health and Medicine, Japan Institute for Health Security, Shinjuku-ku 162-8655, Tokyo, Japan.
  • Experimental Retrovirology Section, HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, United States.
  • Department of Clinical Sciences, Kumamoto University Hospital, Chuo-ku 860-8556, Kumamoto, Japan.

ORCID-Profile: Kohei Tsuji, Nobuyo Higashi-Kuwata, Takahiro Ishii, Hirokazu Tamamura

Förderung

  • University Fellowship Creation Project for Creating Scientific and Technological Innovation
  • Japan Agency for Medical Research and Development
  • Japan Society for the Promotion of Science
  • Support for Pioneering Research Initiated by the Next Generation

Zitieren

APA

Tsuji, K., Kobayakawa, T., Higashi-Kuwata, N., Ishii, T., Shinohara, K., Yamamoto, R., Miura, Y., Wada, N., Mitsuya, H., & Tamamura, H. (2025). SARS-CoV-2 Main Protease Inhibitors Containing 5-Substituted Benzothiazole-2-carbonyl Moieties at the P1′ Site and Their Derivatives. ACS Omega, 10(36), 41608-41619. https://doi.org/10.1021/acsomega.5c05168

Vancouver

Tsuji K, Kobayakawa T, Higashi-Kuwata N, Ishii T, Shinohara K, Yamamoto R, et al. SARS-CoV-2 Main Protease Inhibitors Containing 5-Substituted Benzothiazole-2-carbonyl Moieties at the P1′ Site and Their Derivatives. ACS Omega. 2025;10(36):41608-41619. doi:10.1021/acsomega.5c05168

BibTeX
@article{Tsuji2025,
  author = {Tsuji, Kohei and Kobayakawa, Takuya and Higashi-Kuwata, Nobuyo and Ishii, Takahiro and Shinohara, Kouki and Yamamoto, Ryusei and Miura, Yutaro and Wada, Naoya and Mitsuya, Hiroaki and Tamamura, Hirokazu},
  title = {SARS-CoV-2 Main Protease Inhibitors Containing 5-Substituted Benzothiazole-2-carbonyl Moieties at the P1′ Site and Their Derivatives},
  journal = {ACS Omega},
  year = {2025},
  volume = {10},
  number = {36},
  pages = {41608--41619},
  doi = {10.1021/acsomega.5c05168}
}
Kostenlos starten →